article thumbnail

Rhythm Pharma Drug Lowers BMI in Rare Form of Obesity Rooted in a Dysregulated Brain Pathway

MedCity News

The engineered peptide drug is already approved for two genetically driven types of obesity. The post Rhythm Pharma Drug Lowers BMI in Rare Form of Obesity Rooted in a Dysregulated Brain Pathway appeared first on MedCity News.

Pharma 239
article thumbnail

Nym Rakes In $47M for Autonomous Coding Engine 

MedCity News

The post Nym Rakes In $47M for Autonomous Coding Engine appeared first on MedCity News. Autonomous coding startup Nym raised $47 million. The New York City-based company has 21 provider customers, including Geisinger and Ochsner Health.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA signs off on Adaptimmune's Tecelra as the first engineered cell therapy for a solid tumor

Fierce Pharma

Adaptimmune has won accelerated FDA approval | Adaptimmune has won accelerated FDA approval for Tecelra (afami-cel), a treatment for metastatic or unresectable synovial sarcoma which becomes the first engineered cell therapy for a solid tumor and the first new treatment in the indication in more than a decade.

article thumbnail

‘Serial Killing’ Cell Therapy From Autolus Lands FDA Approval in Blood Cancer

MedCity News

While it goes after the same target as Gilead Sciences’ Tecartus, Autolus engineered its CAR T-therapy with properties that could improve safety, efficacy, and durability. Autolus Therapeutics’ Aucatzyl is now FDA approved for treating advanced cases of B-cell precursor acute lymphoblastic leukemia.

FDA 315
article thumbnail

Adaptimmune’s FDA Approval Marks the First for an Engineered Cell Therapy for Solid Tumors

MedCity News

It’s the first engineered cell therapy approved for treating a solid tumor. The post Adaptimmune’s FDA Approval Marks the First for an Engineered Cell Therapy for Solid Tumors appeared first on MedCity News. The FDA approved Adaptimmune Therapeutics’ Tecelra as a treatment for advanced cases of synovial sarcoma.

article thumbnail

GSK Grabs Rights to Technology That Gets Drugs Across the Blood-Brain Barrier

MedCity News

GSK is licensing an ABL Bio technology yields bispecific antibodies engineered to leverage a certain transmembrane receptor to cross the blood-brain barrier to treat neurodegeneration. GSK is already partnered with Alector, which has monoclonal antibodies in clinical development for Alzheimers disease.

article thumbnail

Fine-Tuning, Prompt Engineering are Keys to Delivering Real Generative AI Solutions to Commercial Pharma Operations Today

MedCity News

Generative AI further enhances the value of prompt engineering by synthesizing important insights from various interactions, including text, images, compliant transcripts, and call notes. By automating this process, generative AI quickly transforms on-the-ground insights into robust analytics.